



Small Molecule R&D Co's Listed on US Exchanges in 2020 (page 1/4)




Company	SYMB	Lead Molecule	Lead Mechanism	Stage	Other Programs	Cap (M)
Schrodinger	SDGR	undisclosed	MALT1-inhibitor for RR-NHL	pre-IND	CDC7, WEE1, HIF2a, SOS1/KRAS	\$5,474
Relay Therapeutics	RLAY	RLY-1971	allosteric SHP2 inhibitor for cancer	Ph. I	FGFR2i, mPI3Ka	\$3,317
Revolution Medicines	RVMD	RMC-4630	SHP2 inhibitor for RAS-addicted cancers	Ph. II	mTORC1, SOS1, KRAS(G12C, G13C, G13D)	\$2,449
Zentalis Pharmaceuticals	ZNTL	ZN-c5	oral SERD for the treatment of ER+/HER2-BC	Ph. II	WEE1, BCL-2, mEGFR	\$2,126
Kymera Therapeutics	KYMR	KT-474	oral IRAK4 degrader for immunology	Ph. I	STAT3, various undisclosed	\$1,998
Atea Pharmaceuticals	AVIR	AT-527	oral nucleotide antiviral prodrug for COVID-19	Ph. III	dengue, HCV NS5B, NS5A, RSV	\$1,970
C4 Therapeutics	CCCC	CFT7455	oral IKZF1/3 degrader for heme. cancers	pre-IND	BRD9, EGFR, BRAFV600E, RET, undisclosed	\$1,787
Harmony Biosciences	HRMY	pitolisant	oral H3 antagonist for narcolepsy	mktd	label expansion in neuro.	\$1,683
PMV Pharmaceuticals	PMVP	PC14586	oral p53 reactivator for p53(Y220C) tumors	Ph. I	p53 R273H	\$1,517
Prelude Therapeutics	PRLD	PRT543	oral PRMT5 inhibitor for cancer	Ph. I	brain penetrant PRMT5i, MCL1i	\$1,498
Kronos Bio	KRON	entospletinib	oral SYK inhibitor for AML	Ph. II	CDK9	\$1,400
Arcutis Biotherapeutics	ARQT	roflumilast	topical PDE4 inhibitor for psoriasis + AD	mktd/Ph. III	JAK1	\$1,375

Small Molecule R&D Co's Listed on US Exchanges in 2020 (page 2/4)




Company	SYMB	Lead Molecule	Lead Mechanism	Stage	Other Programs	Cap (M)
Nurix Therapeutics	NRIX	NX-2127	oral BTK IMiD degrader	Ph. I	Cbl-B, undisclosed	\$1,309
Repare Therapeutics	RPTX	RP-3500	oral ATR inhibitor for solid tumors	Ph. I/II	PKMYT1i, Polθi	\$1,240
Forma Therapeutics	FMTX	olutasidenib	oral, brain-penetrant mIDH1 inhibitor for AML	Ph. II	PKR, CBP/p300, FASN, BET, KRAS	\$1,235
Cullinan Oncology	CGEM	CLN-081 (TAS6417)	oral irreversible EGFR(ex20) inhibitor	Ph. I/IIa	large molecules	\$1,197
Olema Pharmaceuticals	OLMA	OP-1250	oral ER antagonist	Ph. I/II	n/a	\$1,128
Kinnate BioPharma	KNTE	KIN002787	BRAF inhibitor	pre-IND	FGFR2/3, CDK12, undisclosed	\$1,076
Pliant Therapeutics	PLRX	PLN-74809	oral inhibitor of αVβ1/6 integrins	Ph. II	αVβ1, undisclosed	\$1,052
Keros Therapeutics	KROS	KER-047	oral ALK2 kinase inhibitor	Ph. I	TGFβ ligand trap, ActRIIB ligand trap	\$1,046
Aligos Therapeutics	ALGS	ALG-000184	HBV capsid assembly modulator	Ph. I	HBsAg (LM); THR-β SM agonist	\$1,022
iTeos Therapeutics	ITOS	inupadenant	A2AR adenosine receptor inhibitor for I/O	Ph. Ib/IIa	TIGIT mAb	\$894
Praxis Precision Medicines	PRAX	PRAX114	GABA <sub>A</sub> receptor PAM	Ph. II	T-type Ca channel; SCNBA; KCNT1; SCN2A	\$877
ORIC Pharmaceuticals	ORIC	ORIC-101	GR antagonist for solid tumors	Ph. I	CD73, PRC2/EED, EGFR/HER2	\$806

Small Molecule R&D Co's Listed on US Exchanges in 2020 (page 3/4)




Company	SYMB	Lead Molecule	Lead Mechanism	Stage	Other Programs	Cap (M)
Calliditas Therapeutics AB	CALT	Nefecon	oral formulation of budesonide (mkt'd)	Ph. III	n/a	\$722
Annovis Bio	ANVS	ANVS401	oral phenserine for neurological diseases	Ph. II	ibisnorcymcerine	\$649
Tarsus Pharmaceuticals	TARS	TP-03	eye-drop, parasite-specific GABA-Cl inh.	Ph. III	Lyme, rosacea	\$605
Black Diamond Therapeutics	BDTX	BDTX-189	oral irreversible HER2/EGFR(ex20) inhibitor for solid tumors	Ph. I	mEGFR	\$465
Inventiva S.A	IVA	lanifibranor	oral pan-PPAR agonist for NASH	Ph. III	GAG, RORg, YAP-TEAD, TGFβ	\$442
Athira Pharma	ATHA	ATH-1017	oral, brain-penetrant HGF/MET agonist for dementias	Ph. II/III	n/a	\$403
Foghorn Therapeutics	FHTX	FHD-286	allosteric BRG1/BRM ATPase inhibitor for AML	Ph. I	BRD9, BRM, ARID1B, undisclosed	\$379
Spruce Biosciences	SPRB	tildacerfont	oral, brain penetrant CRF1 receptor antagonist	Ph. IIb	n/a	\$257
Orphazyme A/S	ORPH	arimoclomol	heat shock prot. amplifier	NDA rej.	n/a	\$188
Lantern Pharma	LTRN	LP-100	oral DNA damaging agent for cancer	Ph. II	disulfide chemosensitizer	\$166
Ayala Pharmaceuticals	AYLA	AL-101 (BMS-906024)	IV gamma secretase inhibitor for cancer	Ph. II	oral gamma secretase inh.	\$143


Small Molecule R&D Co's Listed on US Exchanges in 2020 (page 4/4)




IMR-687




mometasone furoate




sunitinib




GB0139



LB-100



famciclovir



celecoxib

Company	SYMB	Lead Molecule	Lead Mechanism	Stage	Other Programs	Cap (M)
Imara	IMRA	IMR-687	oral PDE9 inhibitor for hemoglobinopathies	Ph. II	n/a	\$138
Galecto	GLTO	GB0139	inhaled Galectin-3 inhibitor for IPF	Ph. IIb	LOXL2, oral galectin-3	\$133
Lyra Therapeutics	LYRA	LYR-210	implantable mometasone furoate (approved) for chronic sinusitis	Ph. II	n/a	\$110
Graybug Vision	GRAY	GB-102	intravitreal formulation of sunitinib (pan-VEGF inhibitor) for wet AMD	Ph. IIb	intravitreal $\beta$ -adrenergic receptor prodrug	\$109
Metacrine	MTCR	MET409	oral FXR agonist for NASH	Ph. II	n/a	\$103
Inhibikase Therapeutics	IKT	IkT-148009	oral, brain-penetrant Abl kinase inhibitor for PD	Ph. I	BCR-Abl	\$73
Virios Therapeutics	VIRI	IMC-1 (famciclovir + celecoxib)	COX-2/antiviral combo. for HSV-1	Ph. IIa	n/a	\$55
Lixte Biotechnology Holdings	LIXT	LB-100	IV inhibitor of protein phosphatase PP2A for cancer treatment	Ph. I	HDAC	\$40